U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07866768) titled 'CMN LIFU for Enhanced Glymphatic Clearance in Amyloid-Positive MCI' on Aug. 20.
Brief Summary: The goal of this clinical trial is to learn if a wearable ultrasound device, called ATTN201, is safe and easy to use. The study is for adults ages 65 and older who have mild cognitive impairment (MCI) and a buildup of a protein called amyloid in the brain. Amyloid buildup is an early sign of Alzheimer's disease. The ATTN201 device sends low-intensity sound waves to a deep area of the brain that helps control sleep. The aim is to boost deep-sleep brain waves. These brain waves may help the brain clear away waste, including amyloid.
The main...